KYMRvs its industry peers
A metric-by-metric comparison of KYMR against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KYMREsta | $9.4B#4 | — | 6.2x#2 | 239.9x#4 | -16.7%#3 | 39.1%#2 | -891.1%#4 | 20.6%#1 | — | — | — | — |
| MRNA | $57.4B#1 | — | 8.5x#3 | 29.5x#3 | -39.9%#4 | 20.8%#3 | -158.1%#3 | -41.7%#5 | -54.6%#3 | — | — | — |
| TWST | $8.6B#5 | — | 19.4x#6 | 23.0x#2 | 20.3%#2 | 62.8%#1 | -36.2%#2 | -17.4%#4 | -41.4%#2 | — | 435.7%#2 | — |
| ORKA | $6.1B#6 | — | 5.5x#1 | — | — | -25.9%#5 | — | -9.5%#2 | — | — | 503.2%#1 | — |
| VKTX | $3.5B#7 | — | 8.6x#4 | — | — | -227.1%#7 | — | -88.1%#7 | — | — | — | — |
| RVMD | $43.9B#3 | — | 16.9x#5 | — | — | -88.5%#6 | — | -43.4%#6 | — | — | 343.5%#3 | — |
| NTRA | $50.6B#2 | — | 27.8x#7 | 21.9x#1 | 35.9%#1 | -9.3%#4 | -13.4%#1 | -11.4%#3 | -18.0%#1 | — | 103.6%#4 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice